Citadel Advisors
RDY icon

Citadel Advisors’s Dr. Reddy's Laboratories RDY Stock Holding History

Citadel Advisors’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-800
Closed -$10.6K – 14640
2025
Q1 		$10.6K Sell
800
-10,800
-93% -$149K ﹤0.01% 13534
2024
Q4 		$183K Sell
11,600
-18,900
-62% -$284K ﹤0.01% 10591
2024
Q3 		$485K Buy
30,500
+16,500
+118% +$266K ﹤0.01% 8327
2024
Q2 		$213K Buy
14,000
+2,000
+17% +$28.7K ﹤0.01% 9787
2024
Q1 		$176K Buy
12,000
+9,500
+380% +$139K ﹤0.01% 10532
2023
Q4 		$34.8K Sell
2,500
-2,500
-50% -$33.4K ﹤0.01% 12136
2023
Q3 		$66.9K Buy
5,000
+4,000
+400% +$54.1K ﹤0.01% 11384
2023
Q2 		$12.6K Sell
1,000
-5,000
-83% -$58.4K ﹤0.01% 13070
2023
Q1 		$68.3K Buy
6,000
+5,500
+1,100% +$59.4K ﹤0.01% 11774
2022
Q4 		$5.17K Buy
+500
New +$5.39K ﹤0.01% 14028
2022
Q1 		– Sell
-28,000
Closed -$366K – 14410
2021
Q4 		$366K Sell
28,000
-41,000
-59% -$517K ﹤0.01% 10464
2021
Q3 		$899K Buy
69,000
+52,500
+318% +$700K ﹤0.01% 8427
2021
Q2 		$243K Sell
16,500
-33,500
-67% -$468K ﹤0.01% 11756
2021
Q1 		$614K Sell
50,000
-7,500
-13% -$96.3K ﹤0.01% 9239
2020
Q4 		$820K Buy
57,500
+22,500
+64% +$303K ﹤0.01% 7207
2020
Q3 		$487K Buy
35,000
+14,000
+67% +$167K ﹤0.01% 7347
2020
Q2 		$223K Buy
+21,000
New +$214K ﹤0.01% 8368
2018
Q3 		– Sell
-35,000
Closed -$225K – 9606
2018
Q2 		$225K Sell
35,000
-34,000
-49% -$214K ﹤0.01% 7686
2018
Q1 		$451K Sell
69,000
-44,500
-39% -$312K ﹤0.01% 6064
2017
Q4 		$853K Sell
113,500
-28,000
-20% -$202K ﹤0.01% 4885
2017
Q3 		$1.01M Buy
+141,500
New +$1.02M ﹤0.01% 4312

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
AIM
Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Citadel Advisors's RDY Position: Q2 2026 in Review

Citadel Advisors reduced its Dr. Reddy's Laboratories (RDY) stake by 82% in Q2 2026, selling an estimated $4.96M and leaving 79,172 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #7876.

Citadel Advisors first reported a position in RDY in Q4 2013 and has held it in 31 quarters since. The position peaked at $18.7M in Q2 2023. 238 funds tracked by Wall St. Rank hold RDY as of Q2 2026.

  • Citadel Advisors held 79,172 shares of Dr. Reddy's Laboratories worth $1.15M as of Q2 2026.
  • Citadel Advisors sold 367,434 Dr. Reddy's Laboratories shares in Q2 2026, an estimated $4.96M.
  • Dr. Reddy's Laboratories made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #7876 holding.
  • Citadel Advisors first reported a position in Dr. Reddy's Laboratories in Q4 2013 and has held it in 31 quarters since.
  • Citadel Advisors's Dr. Reddy's Laboratories position peaked at $18.7M in Q2 2023.
  • 238 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.